Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.26)
# 432
Out of 5,182 analysts
233
Total ratings
65.06%
Success rate
9.82%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNC Centene | Maintains: Equal-Weight | $38 → $45 | $53.34 | -15.64% | 15 | Mar 4, 2026 | |
| DOCS Doximity | Maintains: Overweight | $65 → $49 | $24.98 | +96.16% | 12 | Feb 6, 2026 | |
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $368.78 | +10.91% | 21 | Jan 23, 2026 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $165.78 | +11.59% | 23 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $255.84 | +19.61% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.53 | +32.80% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.55 | +115.69% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $18.49 | -59.44% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $20.26 | -40.77% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $192.67 | -24.74% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $192.70 | +89.41% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $814.02 | -48.40% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $6.12 | +1,860.78% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $233.63 | +165.38% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $372.68 | +34.16% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $82.09 | +51.05% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $282.90 | +12.41% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $195.24 | -64.15% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $157.77 | +23.60% | 6 | Oct 21, 2020 |
Centene
Mar 4, 2026
Maintains: Equal-Weight
Price Target: $38 → $45
Current: $53.34
Upside: -15.64%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $65 → $49
Current: $24.98
Upside: +96.16%
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $368.78
Upside: +10.91%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $165.78
Upside: +11.59%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $255.84
Upside: +19.61%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.53
Upside: +32.80%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.55
Upside: +115.69%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $18.49
Upside: -59.44%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $20.26
Upside: -40.77%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $192.67
Upside: -24.74%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $192.70
Upside: +89.41%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $814.02
Upside: -48.40%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $6.12
Upside: +1,860.78%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $233.63
Upside: +165.38%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $372.68
Upside: +34.16%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $82.09
Upside: +51.05%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $282.90
Upside: +12.41%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $195.24
Upside: -64.15%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $157.77
Upside: +23.60%